Pfizer (NYSE: PFE) is truly facing a challenge of unprecedented magnitude at the moment. While patent issues are something pharmaceutical companies have struggled with from time to time throughout history, Pfizer is being walloped …
09/14 Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER T.. 09/14 Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER T.. 09/14 BRIEF-Astellas Pharma and Pfizer say positive …
Axovant, which was hit on its stock price immediately as news of the termination spread ... According to Schoenebaum, Axovant believes that "the dose PFE took into phase 2 appears far too low from a receptor occupancy standpoint. …
With or without mid-term elections, the last quarter of 2014 and January of next year could be a bonanza for stock investors ... Pfizer Inc. (NYSE: PFE) trades at a low 14 times earnings and is one of the top pharmaceutical stocks at …
The stock should discover initial support at its 200-day moving average (MA) of $32.28 and subsequent support at its 50-day MA of $31.25. SmarTrend is tracking the current trend status for Pfizer Inc and will alert subscribers who have PFE
Jefferies analyst Jeffrey Holford raised his price target on Buy-rated Pfizer (NYSE: PFE) to $45.00 (from $42.00) and added the stock to the Jefferies "Franchise Picks" list. Holford commented, "We expect PFE shares to significantly …
Pfizer (PFE) said it filed suit in the U.S. District Court for the ... In the absence of such coverage, providers - who depend on reimbursement from insurers - are reluctant to stock biosimilars, even to service Medicare and Medicaid patients …
Pfizer Inc. (NYSE: PFE) shareholders have experienced the short-term euphoria of seeing their stock rally a massive 10 percent from August to September. The stock failed to eclipse key “triple threat” resistance (created by a horizontal line ...
Nearly one-third of Icagen (NASDAQ:ICGN) shareholders have yet to accept Pfizer‘s (NYSE:PFE) $56 million offer for the pain drug ... North Carolina-based Icagen’s common stock had been tendered for the sale. When added to the more …
AZN stock was down $7.28, or 9.07%, in pre-market trading. YTD, the stock is up 37.07%. PFE stock was up 38 cents, or 1.3%, in pre-market trading. YTD, the stock is down 4.4%. Shares of AstraZeneca (AZN) offer a dividend yield of 3.49% …